pIRES-Puro-MGMT
(Plasmid
#187654)
-
PurposeExpresses hMGMT together with the puromycin resistance gene via an IRES.
-
Depositing Lab
-
Sequence Information
Ordering
Item | Catalog # | Description | Quantity | Price (USD) | |
---|---|---|---|---|---|
Plasmid | 187654 | Standard format: Plasmid sent in bacteria as agar stab | 1 | $85 |
Backbone
-
Vector backbonepIRES
- Total vector size (bp) 5883
-
Vector typeMammalian Expression
-
Selectable markersPuromycin
Growth in Bacteria
-
Bacterial Resistance(s)Ampicillin, 100 μg/mL
-
Growth Temperature37°C
-
Growth Strain(s)DH5alpha
-
Copy numberUnknown
Gene/Insert
-
Gene/Insert nameMGMT
-
SpeciesH. sapiens (human)
-
Insert Size (bp)613
-
Entrez GeneMGMT
- Promoter CMV
Cloning Information
- Cloning method Gateway Cloning
- 5′ sequencing primer attB1
- 3′ sequencing primer attB2 (Common Sequencing Primers)
Resource Information
-
Supplemental Documents
Terms and Licenses
-
Academic/Nonprofit Terms
-
Industry Terms
- Not Available to Industry
Trademarks:
- Zeocin® is an InvivoGen trademark.
These plasmids were created by your colleagues. Please acknowledge the Principal Investigator, cite the article in which the plasmids were described, and include Addgene in the Materials and Methods of your future publications.
-
For your Materials & Methods section:
pIRES-Puro-MGMT was a gift from Robert Sobol (Addgene plasmid # 187654 ; http://n2t.net/addgene:187654 ; RRID:Addgene_187654) -
For your References section:
Overcoming Temozolomide Resistance in Glioblastoma via Enhanced NAD(+) Bioavailability and Inhibition of Poly-ADP-Ribose Glycohydrolase. Li J, Koczor CA, Saville KM, Hayat F, Beiser A, McClellan S, Migaud ME, Sobol RW. Cancers (Basel). 2022 Jul 22;14(15). pii: cancers14153572. doi: 10.3390/cancers14153572. 10.3390/cancers14153572 PubMed 35892832